Insights
Depression, Anxiety, and Type 1 Diabetes: What Real-World Data Reveals About a Hidden Risk Factor
For patients with type 1 diabetes (T1D), managing blood sugar is already a constant, demanding task. What happens to that management when a patient also develops depression or anxiety? Surprisingly, real-world evidence on this question has been limited, largely because the data needed to answer…
What Happens When Patients Stop Taking Antidepressants? Here’s What Real-World Data Shows
Antidepressant use in the U.S. has been climbing for years, and so has the length of time patients stay on these medications. That trend recently became a flashpoint: In May 2026, HHS Secretary Robert F. Kennedy Jr. announced a plan aimed at curbing what he…
The AI Productivity Paradox: What’s Holding Pharma Back from Reaching More Patients?
The AI narrative in life sciences has been relentlessly optimistic. More data. Smarter models. Faster insights. And yet the actual output, therapies reaching patients, hasn’t improved at the same speed. If anything, the industry has gotten less productive during the AI era. Why? Because AI…
The Hidden Obesity Population: Why Diagnosis Codes Fail Pharma, Payers, and Patients
More than 60% of clinically obese patients cannot be identified using diagnosis codes alone. For manufacturers, payers, and providers, that means prior authorizations fail, commercial opportunity is underestimated, and real-world evidence built on ICD-10 codes alone systematically miss eligible patients. Anti-obesity medications are the most…
Cardiovascular, Renal, and Hepatic Biomarkers Outside Guideline-Recommended Thresholds: Prevalence and Determinants in Type 1 Diabetes
T1D Exchange published research in Diabetes Technology & Therapeutics using NorstellaLinQ lab data linked to their T1D patient registry and wearable device data. The objective of the study was to evaluate the prevalence of cardiovascular, renal, and hepatic biomarkers that fall outside guideline-based thresholds in…
Why an AI-Native Biotech Chose Norstella
Drug development has made huge scientific progress over the last decade. The way we run clinical development has changed far less. Timelines are still long. Costs are still high. And most of the risk is decided before a trial even begins—we just don’t treat it…
